General Information of Drug (ID: DMA0RI8)

Drug Name
PMID29649907-Compound-INT767 Drug Info
Cross-matching ID
TTD Drug ID
DMA0RI8

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTT
Drug Status:
Approved Drug(s)
Clinical Trial Drug(s)
Patented Agent(s)
Preclinical Drug(s)
Investigative Drug(s)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Chenodiol DMQ8JIK Cholelithiasis DC11 Approved [2]
Guggulsterone DMP7LK1 Osteoarthritis FA00-FA05 Approved [3]
Obeticholic acid DM3Q1SM Primary biliary cholangitis DB96.1 Approved [4]
Bevacizumab + Trastuzumab DM9CEI5 Breast cancer 2C60-2C65 Phase 3 [2]
GS-9674 DM936V7 Primary sclerosing cholangitis DB96.2 Phase 3 [5]
Apomine DM6B9HP Osteopetrosis LD24.10 Phase 2 [6]
LJN452 DM3XRUH Primary biliary cholangitis DB96.1 Phase 2 [7]
EYP001 DM5PBLM Non-alcoholic steatohepatitis DB92.1 Phase 2 [8]
EDP-305 DMGJYZ8 Non-alcoholic steatohepatitis DB92.1 Phase 2 [9]
LMB763 DMQOXNL Diabetic nephropathy GB61.Z Phase 2 [10]
⏷ Show the Full List of 10 Drug(s)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Sodium taurocholate DM3GO0J Type-2 diabetes 5A11 Phase 1/2 [11]
PMID29649907-Compound-8 DMV2D5M N. A. N. A. Patented [1]
INT-767 DMRJ9P4 Hepatic fibrosis DB93.0 Preclinical [12]
XL475 DMD8TNK Type-2 diabetes 5A11 Preclinical [13]
INT-777 DMTPB8A Metabolic disorder 5C50-5D2Z Investigative [14]
Bile acid DMIY2HW Discovery agent N.A. Investigative [15]
⏷ Show the Full List of 6 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Farnesoid X-activated receptor (FXR) TTS4UGC NR1H4_HUMAN Agonist [1]
G-protein coupled bile acid receptor 1 (GPBAR1) TTSDVTR GPBAR_HUMAN Agonist [1]

References

1 Farnesoid X receptor modulators 2014-present: a patent review.Expert Opin Ther Pat. 2018 May;28(5):351-364.
2 Lithocholic acid decreases expression of bile salt export pump through farnesoid X receptor antagonist activity. J Biol Chem. 2002 Aug 30;277(35):31441-7.
3 Effect of guggulsterone and cembranoids of Commiphora mukul on pancreatic phospholipase A(2): role in hypocholesterolemia. J Nat Prod. 2009 Jan;72(1):24-8.
4 2016 FDA drug approvals. Nat Rev Drug Discov. 2017 Feb 2;16(2):73-76.
5 The Nonsteroidal Farnesoid X Receptor Agonist Cilofexor (GS-9674) Improves Markers of Cholestasis and Liver Injury in Patients With Primary Sclerosing Cholangitis. Hepatology. 2019 Sep;70(3):788-801.
6 The nuclear receptors FXR and LXRalpha: potential targets for the development of drugs affecting lipid metabolism and neoplastic diseases. Curr Pharm Des. 2001 Mar;7(4):231-59.
7 FXR modulators for enterohepatic and metabolic diseases.Expert Opin Ther Pat. 2018 Nov;28(11):765-782.
8 Clinical pipeline report, company report or official report of ENYO Pharma.
9 A novel non-bile acid FXR agonist EDP-305 potently suppresses liver injury and fibrosis without worsening of ductular reaction. Liver Int. 2020 Jul;40(7):1655-1669.
10 Nidufexor (LMB763), a Novel FXR Modulator for the Treatment of Nonalcoholic Steatohepatitis. J Med Chem. 2020 Apr 23;63(8):3868-3880.
11 Bile acids and sphingosine-1-phosphate receptor 2 in hepatic lipid metabolism.Acta Pharmaceutica Sinica B Volume 5, Issue 2, March 2015, Pages 151-157.
12 FXR/TGR5 Dual Agonist Prevents Progression of Nephropathy in Diabetes and Obesity. J Am Soc Nephrol. 2018 Jan;29(1):118-137.
13 Clinical pipeline report, company report or official report of Exelixis (2011).
14 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 37).
15 Synthesis and SAR of 2-aryl-3-aminomethylquinolines as agonists of the bile acid receptor TGR5. Bioorg Med Chem Lett. 2010 Oct 1;20(19):5718-21.